Goedemorgen doe mij maar een bakje koffie.
Ja morgen gaat het dan gebeuren, eindelijk hebben we weer zo'n belangrijk land binnen.
En Misty ik wist niet dat dit onder leiding was van een van onze kritische forumleden.
Je zie maar weer, dat de wereld gek in elkaar steekt.
Vanavond drinken we hier op.
Ghijs :-)
Pharming signs commercialization agreement with Camobs for Ruconest in Friesland
17 October 2011
Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it has entered into an agreement with Camobs a privately owned Fries pharmaceutical company, for the commercialization of Ruconest® (recombinant human C1 inhibitor) in Friesland for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).
Under the agreement, Camobs will pay Pharming for completion of certain commercial, regulatory and clinical milestones.Camobs will purchase its commercial supply of Ruconest from Pharming at a supply price, based on a percentage of net sales of Ruconest. The number of HAE patients in Friesland is estimated at approximately 10. Camobs anticipate to launch Ruconest in 2012.
Sijmen de Vries, CEO of Pharming, commented: "We are pleased to have taken a another step towards making Ruconest, an innovative, highly effective and safe replacement therapy, available to HAE patients globally. In Camobs we have a strong commercialization partner with a proven track record in this region and strong presence in the immunology therapeutic area."
Robertus Nurks, CEO of Camobs, said: "We are delighted to have concluded an agreement with Pharming to market Ruconest in Friesland. We have been active in the Allergy and Immunology fields for many years and this is an important step in the company`s strategy to strengthen our presence and expand our portfolio in this therapeutic area."
Ruconest® is a human protein developed through Pharming`s proprietary technology where the human protein is expressed in milk of transgenic rabbits. Pharming is developing Rhucin/Ruconest for treatment of patients with acute attacks of Hereditary Angioedema. HAE is a human genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1-inhibitor, resulting in an overreaction of the immune system. The disease is characterized by unpredictable and debilitating episodes of intense swelling of the extremities, face, trunk, genitals, abdomen and upper airway, which may last up to five days when untreated. In addition to the life-threatening nature of the disease in case of laryngeal attacks, quality of life for individuals with the disease may be seriously impaired. Approximately one in 30,000 individuals (1:10,000 - 1:50,000) suffers from HAE with an average of approximately eight acute attacks per year.